Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026)

Alnylam Pharmaceuticals has reported Common Equity for 18 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 152.35% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 152.35% YoY), and the FY2025 full-year result was $789.2 million, up 1076.33% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, up from $789.2 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2026, with the low at -$408.1 million in Q2 2023.
• Historically, Common Equity has averaged $114.7 million across 5 years, with a median of $32.4 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity plunged 331.84% — and 2025, when it surged 8270.56%.
• Alnylam Pharmaceuticals' Common Equity stood at -$158.2 million in 2022, then slumped by 39.45% to -$220.6 million in 2023, then surged by 130.41% to $67.1 million in 2024, then jumped by 1076.33% to $789.2 million in 2025, then jumped by 36.27% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $789.2 million (Q4 2025), and $233.9 million (Q3 2025), per Business Quant data.